1. Home
  2. CYRX vs ADCT Comparison

CYRX vs ADCT Comparison

Compare CYRX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYRX

CryoPort Inc.

HOLD

Current Price

$14.77

Market Cap

419.3M

Sector

Health Care

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.11

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
ADCT
Founded
1999
2011
Country
United States
Switzerland
Employees
1100
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
419.3M
431.2M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
CYRX
ADCT
Price
$14.77
$1.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$13.31
$7.75
AVG Volume (30 Days)
816.2K
3.2M
Earning Date
05-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
156.22
30.86
EPS
N/A
N/A
Revenue
$176,177,000.00
$81,357,000.00
Revenue This Year
$11.06
N/A
Revenue Next Year
$8.45
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$6.69
$0.78
52 Week High
$16.73
$4.98

Technical Indicators

Market Signals
Indicator
CYRX
ADCT
Relative Strength Index (RSI) 53.76 19.26
Support Level $14.29 $0.78
Resistance Level $16.73 $4.77
Average True Range (ATR) 0.64 0.16
MACD -0.24 -0.03
Stochastic Oscillator 14.52 11.78

Price Performance

Historical Comparison
CYRX
ADCT

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: